OBJECTIVE: Given the renewed interest in the role of sex differences in @entity161 , we undertook a post hoc analysis to determine whether sex differences in treatment response were present among outpatients with @entity161 who received @entity1090 in an 8-week, open-label, Phase IV clinical study. METHOD: We evaluated 330 adult @entity1 (232 @entity1 , 98 @entity1 ) with a DSM-III-R diagnosis of @entity161 for safety and 292 (206 @entity1 , 86 @entity1 ) for efficacy. @entity910 were discontinued at study entry. Treatment with @entity1090 was initiated at a dosage of 2 mg daily, increased to the target dosage of 6 mg daily by day 3, and maintained at 6 mg daily until day 14. The dosage was then maintained at 6 mg daily, increased or decreased by 2 mg daily each week, based on the @entity1 's response. @entity1090 treatment was given for 8 weeks; the permitted dosage range was 4 mg to 10 mg daily. RESULTS: Both male and female @entity1 responded well to @entity1090 treatment; by the final assessment day, they had experienced decreases from baseline in their total Positive and Negative Syndrome Scale (PANSS) scores of 41.0% and 36.5%, respectively. Most male (77%) and female (78%) @entity1 were considered to be PANSS responders: @entity1090 was effective against both the positive and negative symptoms of @entity161 . Both sexes showed improvements over baseline in the incidence and severity of @entity304 , @entity3519 , and @entity910 . No significant (P > 0.05) sex differences in treatment response were observed for any of the efficacy outcomes or in the incidence and severity of @entity21 ( @entity21 ). CONCLUSIONS: In this population of outpatients with chronic @entity161 , both @entity1 and @entity1 responded well to flexible doses of @entity1090 . No significant sex differences were evident either in treatment response or in neurological side effects. The absence of sex differences in response to @entity1090 treatment may obviate the need for a sex-based differential dosing in @entity161 management.

XXXX treatment of outpatients with @entity161 : no evidence of sex differences in treatment response.

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'patient', 'men'] @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism'] @entity910 :: ('MESH:D004409', 'Disease') :: ['Antipsychotic and antiparkinsonian medications', 'dyskinesia'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity3519 :: ('MESH:D004421', 'Disease') :: ['dystonia'] @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms', 'EPS'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone', 'Risperidone']
@entity1090 :: (MESH:D018967,Chemical) :: ['Risperidone']
